KD Logo

Jefferies Upgrades Arbutus Biopharma Corp (ABUS) to a Buy from a Hold

Arbutus Biopharma Corp’s filing revealed that its Officer Sofia Michael J. acquired Company’s shares for reported $0.82 million on Mar 24 ’25. In the deal valued at $3.28 per share,250,000 shares were bought.

Then, Sofia Michael J. bought 150,000 shares, generating $480,000 in total proceeds.

Before that, Sofia Michael J. bought 100,000 shares. Arbutus Biopharma Corp shares valued at $338,000 were divested by the Officer at a price of $3.38 per share.

Jefferies upgraded its Arbutus Biopharma Corp [ABUS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late February with a ‘”a Hold”‘ rating. H.C. Wainwright began covering ABUS with “Buy” recommendation on December 17, 2020.

Price Performance Review of ABUS

On Tuesday, Arbutus Biopharma Corp [NASDAQ:ABUS] saw its stock fall -0.59% to $3.37. Over the last five days, the stock has gained 5.31%. Arbutus Biopharma Corp shares have risen nearly 3.06% since the year began. Nevertheless, the stocks have risen 32.16% over the past one year. While a 52-week high of $4.72 was reached on 02/25/25, a 52-week low of $2.30 was recorded on 03/12/25. SMA at 50 days reached $3.33, while 200 days put it at $3.59.

Levels Of Support And Resistance For ABUS Stock

The 24-hour chart illustrates a support level at 3.32, which if violated will result in even more drops to 3.27. On the upside, there is a resistance level at 3.41. A further resistance level may holdings at 3.45. The Relative Strength Index (RSI) on the 14-day chart is 52.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.33%. Stochastics %K at 61.47% indicates the stock is a holding.

How much short interest is there in Arbutus Biopharma Corp?

A steep rise in short interest was recorded in Arbutus Biopharma Corp stocks on 2025-03-14, growing by 2.36 million shares to a total of 9.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 7.21 million shares. There was a rise of 24.67%, which implies that there is a positive sentiment for the stock.

Most Popular